BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 37373187)

  • 1. Role of Histone Deacetylases in the Pathogenesis of Salivary Gland Tumors and Therapeutic Targeting Options.
    Manou M; Kanakoglou DS; Loupis T; Vrachnos DM; Theocharis S; Papavassiliou AG; Piperi C
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
    Hanikoglu A; Hanikoglu F; Ozben T
    Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The emerging roles of HDACs and their therapeutic implications in cancer.
    Hai R; Yang D; Zheng F; Wang W; Han X; Bode AM; Luo X
    Eur J Pharmacol; 2022 Sep; 931():175216. PubMed ID: 35988787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress in discovery and development of natural inhibitors of histone deacetylases (HDACs) as anti-cancer agents.
    Wahi A; Jain P; Sinhari A; Jadhav HR
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Feb; 397(2):675-702. PubMed ID: 37615708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the Expression and Role of Histone Acetylation and Deacetylation in Dental Pulp Cells.
    Yamauchi Y; Duncan HF
    Methods Mol Biol; 2023; 2588():279-293. PubMed ID: 36418694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone Deacetylase Modifications by Probiotics in Colorectal Cancer.
    Salek Farrokhi A; Mohammadlou M; Abdollahi M; Eslami M; Yousefi B
    J Gastrointest Cancer; 2020 Sep; 51(3):754-764. PubMed ID: 31808058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced Transcriptional Signature and Expression of Histone-Modifying Enzymes in Salivary Gland Tumors.
    Manou M; Loupis T; Vrachnos DM; Katsoulas N; Theocharis S; Kanakoglou DS; Basdra EK; Piperi C; Papavassiliou AG
    Cells; 2023 Oct; 12(20):. PubMed ID: 37887281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unmasking the pathological and therapeutic potential of histone deacetylases for liver cancer.
    Zhao J; Gray SG; Greene CM; Lawless MW
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):247-256. PubMed ID: 30791763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option.
    Korfei M; Mahavadi P; Guenther A
    Cells; 2022 May; 11(10):. PubMed ID: 35626663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updating a Strategy for Histone Deacetylases and Its Inhibitors in the Potential Treatment of Cerebral Ischemic Stroke.
    Xu Y; Wang Q; Chen J; Ma Y; Liu X
    Dis Markers; 2020; 2020():8820803. PubMed ID: 32963637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Histone Deacetylases (HDACs) in Epilepsy and Epileptogenesis.
    Citraro R; Leo A; Santoro M; D'agostino G; Constanti A; Russo E
    Curr Pharm Des; 2017; 23(37):5546-5562. PubMed ID: 29076408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDAC 3-selective inhibitor RGFP966 demonstrates anti-inflammatory properties in RAW 264.7 macrophages and mouse precision-cut lung slices by attenuating NF-κB p65 transcriptional activity.
    Leus NG; van der Wouden PE; van den Bosch T; Hooghiemstra WTR; Ourailidou ME; Kistemaker LE; Bischoff R; Gosens R; Haisma HJ; Dekker FJ
    Biochem Pharmacol; 2016 May; 108():58-74. PubMed ID: 26993378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic modulation: Research progress on histone acetylation levels in major depressive disorders.
    Meng Y; Du J; Liu N; Qiang Y; Xiao L; Lan X; Ma L; Yang J; Yu J; Lu G
    J Drug Target; 2023 Feb; 31(2):142-151. PubMed ID: 36112185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors.
    Bush EW; McKinsey TA
    Circ Res; 2010 Feb; 106(2):272-84. PubMed ID: 20133912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomas.
    Manta A; Kazanas S; Karamaroudis S; Gogas H; Ziogas DC
    Oncol Res; 2022; 30(5):211-219. PubMed ID: 37305348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Food Bioactive HDAC Inhibitors in the Epigenetic Regulation of Heart Failure.
    Evans LW; Ferguson BS
    Nutrients; 2018 Aug; 10(8):. PubMed ID: 30126190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Epigenetic mechanisms and alcohol use disorders: a potential therapeutic target].
    Legastelois R; Jeanblanc J; Vilpoux C; Bourguet E; Naassila M
    Biol Aujourdhui; 2017; 211(1):83-91. PubMed ID: 28682229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone Deacetylases in Kidney Physiology and Acute Kidney Injury.
    Hyndman KA
    Semin Nephrol; 2020 Mar; 40(2):138-147. PubMed ID: 32303277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of HDACs in normal and malignant hematopoiesis.
    Wang P; Wang Z; Liu J
    Mol Cancer; 2020 Jan; 19(1):5. PubMed ID: 31910827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HDACs as an emerging target in endocrine tumors: a comprehensive review.
    Klieser E; Neumayer B; Di Fazio P; Mayr C; Neureiter D; Kiesslich T
    Expert Rev Endocrinol Metab; 2023 Mar; 18(2):143-154. PubMed ID: 36872882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.